CardioExchange Archive

November 6th, 2012

AHA — There’s an App for That!

Amit Shah, MD, MSCR

AHA.12 may be a haven for the tech-savvy. What tech tricks help you stay organized?

---

November 6th, 2012

Breadth vs. Depth at AHA

Tariq Ahmad, MD, MPH

A tight focus works well for this fellow with a special interest in heart failure, but if you don’t have a subspecialty, does going for breadth work better?

---

November 6th, 2012

What Tack to Take in Thinking about TACT?

Reva Balakrishnan, MD, MPH

A fellow encounters a little-understood intervention and startling study results; can informal discussions with senior faculty at AHA provide insight?

---

November 6th, 2012

Using the Internet to Learn from Leaders in Cardiology

Tariq Ahmad, MD, MPH

Fellows use apps, the Internet, and social media to make the most of AHA 12

---

November 6th, 2012

Acknowledging our Mentors, Both Faculty and Peers

Megan Coylewright, MD MPH

How best to show thanks to those who have given so generously?

---

November 6th, 2012

Cardiology Circles and the AHA

Tariq Ahmad, MD, MPH

A fellow spends much of his time at AHA deepening his connections with colleagues from back home. Or should he be trying to meet new people?

---

November 6th, 2012

Late-Breaking Trials vs. Abstract Oral Sessions

Eiman Jahangir, MD

One fellow shares why he prefers to spend his time at AHA 2012 attending the abstract oral sessions.

---

November 5th, 2012

Early Look: New Methods to Enhance Cholesterol Efflux

Larry Husten, PHD

Although clinical trials of HDL-boosting CETP inhibitors have so far failed to produce positive results, many other avenues of HDL-related research remain active. Conference attendees got a glimpse of the very early phases of two intriguing lines of research in this area on Monday. Apoliporotein A-I is thought to be the key HDL component that […]

---

November 5th, 2012

What’s the Value of the Expo?

Reva Balakrishnan, MD, MPH

This fellow found little value in the Expo floor except for some laughs. Has your experience been different?

---

November 5th, 2012

Dalcetrapib: Another HDL-Raising CETP Inhibitor Bites the Dust

Larry Husten, PHD

Another HDL-raising CETP inhibitor has failed to demonstrate cardiovascular benefit in a large clinical trial. With the presentation of the dal-OUTCOMES trial at the American Heart Association in Los Angeles and simultaneous publication in the New England Journal of Medicine, dalcetrapib joins torceptrapib on the list of once-promising CETP inhibitors. In dal-OUTCOMES, 15,871 patients with a […]

---